Multiple Myeloma Patient and Prescriber Audiences
In our Audience Quality Test, the multiple myeloma audience held 3.01× more high-fit households than the U.S. population, and 2.23× more qualified households. Brands can reach patients and the prescribers who treat them, with results reported every week. At $1.50 to $3.00 CPM, these audiences are priced at approximately 50% or less of the market rate.
Qualified audience
Every household and prescriber is scored 0 to 100 for fit to this condition. You buy only the tiers that qualify.
$1.50 to $3.00 CPM
Priced at approximately 50% or less of the market rate for pharma audiences.
Weekly measurement
Qualified reach, lift against the national baseline, and reach by state, reported every week.
Patients · DTC validated
- Households in test audience
- 3.2M
- High-fit people, national (score 73+)
- 72K
- Qualified people, national (score 55+)
- 61.1M
- Digitally active, qualified
- 25.6M
Share of households clearing the high-fit bar (score 73+). Qualified tier (score 55+): 54.1% in the test audience vs 24.3% nationally.
Prescribers · HCP active Type 1 NPIs
| Specialty | NPIs | At home |
|---|---|---|
| Treating | 25,299 | 15,991 |
| Hematology & medical oncology | 23,800 | 15,058 |
| Hematology | 1,499 | 933 |
| Referring | 340,787 | 209,564 |
| Nephrology | 13,652 | 8,728 |
| Family & internal medicine | 327,135 | 200,836 |
| Total prescribers | 366,086 | 225,555 |
Counted by primary NUCC taxonomy in the CMS NPPES registry (September 2026). "At home" means matched to a home address in Semcasting's NPI file, for reach on CTV, streaming and display. Referring counts exclude doctors already counted as treating.
Where qualified patients concentrate top states by share
- New Hampshire
- Maryland
- Rhode Island
- Florida
- South Dakota
- Maine
Common questions
How many prescribers treat multiple myeloma?
25,299 active Type 1 NPIs in the treating specialties (hematology & medical oncology and hematology), 15,991 of them matched to a home address for CTV, streaming and display. Another 340,787 referring prescribers are counted separately. Counts come from the CMS NPPES registry, September 2026.
How was the multiple myeloma patient audience validated?
In Semcasting's Audience Quality Test, the multiple myeloma audience held 3.01x more high-fit households than the U.S. population (score 73 or higher) and 2.23x more qualified households (score 55 or higher). During a campaign the same comparison runs every week on the households actually reached.
Does the multiple myeloma audience use diagnosis, claims or prescription data?
No. Patient audiences are built from peer-reviewed, population-level public health reporting and population surveys, scored against Semcasting's national adult file. No diagnosis records, claims, prescriptions or PHI are used, and the score says nothing about any one person's health.
Evidence base primary sources for multiple myeloma
- Physician-reported registryNIH National Cancer Institute SEER registries
- Disease associationMultiple Myeloma Research Foundation
- Population surveyCDC PLACES: Cancer (state and county)
How the audience is built
Patient counts for multiple myeloma come from physician-reported registries, diagnostic population surveys, and federal (CDC, CMS, NIH) and disease-association reporting, listed above. Each of 251.7M U.S. adult records is scored 0 to 100 for fit to those published patient profiles by age, gender and income, weighted by geographic prevalence (CDC PLACES: Cancer (CANCER)). Qualified means a score of 55 or higher. High-fit means 73 or higher.
How quality is confirmed
Audience quality has historically been confirmed through holdout sampling: a delivered audience is compared with the full national panel at the same fixed score cutoffs, and the difference is reported as lift. During a campaign, the same comparison runs every week on the households actually reached.
What it is not
Qualified audiences are not built from modeled claims data extrapolated from a few locations. They come from peer-reviewed, population-level public health reporting on patient profiles and population surveys. No diagnosis records, claims, prescriptions or PHI are used, and the score says nothing about any one person's health.